Industry: Biotechnology

Sector: Healthcare

Marizyme, Inc., a multi-technology biomedical company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating chronic wounds and burns, thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment; and MAR-FG-001, a fat grafting technology for use in fat grafting procedures. The company was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.

MARIZYME INC is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.